Source: BioSpace

InflaRx: InflaRx Reports Full Year 2022 Financial and Operating Results

InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, today announced financial and operating results for the year ended December 31, 2022.

Read full article »
Annual Revenue
Niels C. Riedemann's photo - Co-Founder & CEO of InflaRx

Co-Founder & CEO

Niels C. Riedemann

CEO Approval Rating


Read more